LGND

Ligand Pharmaceuticals Incorporated

Price

$291.71

return (12m)

104.85%

p/e

37.85

p/bv

5.83

DIVIDEND YIELD

0.00%

LGND price

Ligand Pharmaceuticals

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment LGND

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-7.06%

3 months

31.75%

1 year

104.85%

2 years

194.54%

5 years

165.47%

10 years

152.48%

Fundamentals LGND

Valuation

P/E

37.85

Sector -3.98

Industry -3.98

P/BV

5.83

Sector 2.00

Industry 2.00

P/Revenue (PSR)

21.18

Sector -4.41

Industry -4.41

EV/EBITDA

-382.35

Sector -245.01

Industry -245.01

EV/EBIT

-242.89

Sector -666.51

Industry -666.51

P/EBITDA

25.98

Sector -4.07

Industry -4.07

P/EBIT

30.51

Sector -4.24

Industry -4.24

P/Total Assets

3.79

Sector 1.40

Industry 1.40

P/Net Current Assets

17.58

Sector -11.65

Industry -11.65

P/Working Capital

7.05

Sector -10.95

Industry -10.95

EPS

7.68

Sector -2.20

Industry -2.20

BVPS

49.87

Sector 1.95

Industry 1.95

Efficiency

Gross Margin

95.27%

Sector 36.05%

Industry 36.05%

EBITDA Margin

-27.65%

Sector -16,817.20%

Industry -16,817.20%

EBIT Margin

-43.52%

Sector -4,256,841.62%

Industry -4,256,841.62%

Operating Margin

36.88%

Sector -38.74%

Industry -38.74%

Net Profit Margins

55.94%

Sector -39.50%

Industry -39.50%

Asset Turnover

0.03

Sector 0.03

Industry 0.03

Profitability

ROE

15.40%

Sector -66.41%

Industry -66.41%

ROA

10.02%

Sector -66.55%

Industry -66.55%

ROIC

5.16%

Sector -1,703.97%

Industry -1,703.97%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

21.28

Sector 2.90

Industry 2.90

Net Debt / EBITDA

24.10

Sector -14.63

Industry -14.63

Net Debt / EBIT

15.31

Sector -7.24

Industry -7.24

Net Debt / Equity

-0.35

Sector -33,201.65

Industry -33,201.65

Gross Debt / Equity

0.45

Sector -0.02

Industry -0.02

Equity/Assets

0.65

Sector 0.42

Industry 0.42

Liabilities/Assets

0.35

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

2.59%

Sector -

Industry -

5Y Earnings CAGR

21.86%

Sector -

Industry -

FAIR VALUE OF Ligand Pharmaceuticals ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$291.71

Fair Value

$92.83

Upside Return potential.

-68.18%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals LGND

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
LGND	37.85	5.83	15.40%	0.00%	$5.81 B	55.94%
JNJ	29.40	7.28	24.76%	2.04%	$618.44 B	21.48%
PFE	18.75	1.55	8.29%	6.97%	$140.44 B	11.83%
ABBV	71.07	0.00	-%	2.66%	$448.43 B	9.80%
NVO	11.00	6.65	60.40%	3.96%	$208.75 B	37.15%
MRK	35.97	7.00	19.45%	2.58%	$321.35 B	13.59%
AZN	25.16	5.22	20.74%	1.89%	$262.79 B	17.02%
GILD	17.55	6.90	39.33%	2.47%	$161.73 B	30.99%
BMY	14.12	5.87	41.59%	3.91%	$131.06 B	18.87%
ZTS	12.23	10.00	81.75%	2.69%	$32.33 B	27.79%
REGN	17.58	2.40	13.65%	0.49%	$76.11 B	27.86%
AMGN	26.41	22.42	84.87%	2.57%	$206.02 B	20.96%
HALO	27.82	44.19	158.82%	0.00%	$9.70 B	23.13%
MCK	22.00	-125.59	-570.98%	0.38%	$104.74 B	1.18%
VRTX	27.75	6.22	22.41%	0.00%	$120.39 B	35.51%
CAH	34.61	-20.14	-58.20%	0.89%	$53.82 B	0.62%
HRMY	13.88	2.22	16.00%	0.00%	$2.02 B	16.20%
BIIB	36.30	1.61	4.43%	0.00%	$30.30 B	8.32%
MEDP	32.46	36.77	113.29%	0.00%	$15.95 B	17.67%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

LGND Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

DRAG THE FRAME TO SEE MORE DATA

type	Ex - Dividend Date	payment date	value
Dividends	04/03/2007	04/19/2007	15.00000000

ABOUT Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated

Average Investor10 user rating

4.0 (0 people)

United States

39 years

Founded: 1987

1995

Time since IPO - 31 years

115

Employees

Ligand Pharmaceuticals Incorporated (United States) is listed on the Nasdaq and has a market capitalization of $5.81 billion, with shareholders equity totaling $997.32 million.

The company employs approximately 115 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Ligand Pharmaceuticals Incorporated reported $274.48 million in revenue, generating net income of $153.55 million.

Key financial metrics include a P/E ratio of 37.85, a price-to-book (P/B) ratio of 5.83, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker LGND.

Market cap

$5.81 billion

Net worth

$997.32 million

$997,320,000.00

Assets

$1.53 billion

$1,532,110,000.00

Total Shares Outstanding

20.00 million

20,000,000

Average Daily Trading Volume

$387.80 Thousand

$387,798.00

Sector

Health Care

Industry

Biotechnology

LGND

LGND revenue and profits

Financial Results LGND

DRAG THE FRAME TO SEE MORE DATA

LGND cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$881.98 33,67% (12M)

P/E

22.00

0.38%

ROE

-570.98%

P/BV

-125.59

CAH - Cardinal Health

$238.75 57,26% (12M)

P/E

34.61

0.89%

ROE

-58.20%

P/BV

-20.14

JNJ - Johnson & Johnson

$256.80 54,25% (12M)

P/E

29.40

2.04%

ROE

24.76%

P/BV

7.28

ABBV - AbbVie

$244.60 28,01% (12M)

P/E

71.07

2.66%

ROE

P/BV

0.00

MRK - Merck & Co.

$128.41 66,15% (12M)

P/E

35.97

2.58%

ROE

19.45%

P/BV

7.00

AZN - AstraZeneca

$160.68 11,84% (12M)

P/E

25.16

1.89%

ROE

20.74%

P/BV

5.22

NVO - Novo Nordisk

$47.02 --3,51% (12M)

P/E

11.00

3.96%

ROE

60.40%

P/BV

6.65

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$881.98 33,67% (12 M)

P/L

22.00

0.38%

ROE

-570.98%

P/VP

-125.59

CAH - Cardinal Health

$238.75 57,26% (12 M)

P/L

34.61

0.89%

ROE

-58.20%

P/VP

-20.14

JNJ - Johnson & Johnson

$256.80 54,25% (12 M)

P/L

29.40

2.04%

ROE

24.76%

P/VP

7.28

ABBV - AbbVie

$244.60 28,01% (12 M)

P/L

71.07

2.66%

ROE

P/VP

0.00

MRK - Merck & Co.

$128.41 66,15% (12 M)

P/L

35.97

2.58%

ROE

19.45%

P/VP

7.00

AZN - AstraZeneca

$160.68 11,84% (12 M)

P/L

25.16

1.89%

ROE

20.74%

P/VP

5.22

NVO - Novo Nordisk

$47.02 --3,51% (12 M)

P/L

11.00

3.96%

ROE

60.40%

P/VP

6.65

Frequently Asked Questions

What is the price of Ligand Pharmaceuticals (LGND) today?

A cotação de Ligand Pharmaceuticals (LGND) hoje está em US$ 291.71, com uma variação de 104.85% em relação ao último ano. A cotação de Ligand Pharmaceuticals (LGND) iniciou o ano negociando na casa dos US$ 189.07 e hoje está em US$ 291.71. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Ligand Pharmaceuticals (LGND) e dados de ações do Ibovespa e mercados internacionais.

Quando Ligand Pharmaceuticals (LGND) paga dividendos?

Ligand Pharmaceuticals (LGND) não distribuiu dividendos no último ano.

Is Ligand Pharmaceuticals (LGND) a good investment?

Atualmente, Ligand Pharmaceuticals (LGND) está cotada a US$ 291.71, com um P/L de 37.85, representando um desvio de -8,850% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 104.85 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 104.85%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Ligand Pharmaceuticals (LGND) stock?

Investir em ações de Ligand Pharmaceuticals (LGND) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Ligand Pharmaceuticals (LGND) yield today?

A rentabilidade de Ligand Pharmaceuticals (LGND) foi de -7.06% no último mês, 104.85% no último ano e 165.47% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Ligand Pharmaceuticals (LGND) hoje, o investimento total seria de US$ 29,171.01, com base na cotação atual de US$ 291.71.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 59,756.81
Em 5 anos: US$ 77,440.28
Em 10 anos: US$ 73,650.97

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

LGND

Ligand Pharmaceuticals Incorporated

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment LGND

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

Graham's Fair Value

current DY: 0.00%

5-year average DY: 0.00%

type

Ex - Dividend Date

payment date

value

ABOUT Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated

United States

39 years

1995

115

PROFIT X PRICE LGND

Financial Results LGND

LGND cash flow

Asset, Revenue and Profit Growth - LGND

LGND balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

NVO - Novo Nordisk

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

NVO - Novo Nordisk

Frequently Asked Questions